Described herein are durable surface coatings, which are useful for medical devices, and processes for preparing the coatings.
Hydrophilic coatings used on medical devices, including guidewires and catheters, are generally on the order of microns thick. Upon hydration and repetitive use such coatings have been known to shed particulates by, for example, separating from the access device surface during interventional procedures. Most coatings are mechanically adhered to a surface. Forces exerted during insertion and navigation of an access device can shear the coatings and release particulate matter that may cause various medical complications depending on the particulate size, including blood vessel ischemia.
Thus, there remains a need for improved surface coatings that are useful for, at least, medical devices.
Described herein are surface coatings. In some embodiments the surface coatings provide improved durability, i.e. a reduced propensity to shed coating particulate upon hydration of the coating or repetitive use of a device on which the coating is disposed. In some embodiments, the surface coatings can be disposed on a substrate, which can be associated with a medical device such as a catheter, a guide wire, or an implantable medical device such as a stent. Implantable medical devices can include, but are not limited to, flat coupons, hypo tubes, wires, woven wires, or laser cut objects. In some embodiments, the medical device is one used to access a lumen of a subject's body.
Described herein are substrate coatings, i.e. durable surface coatings, and processes for preparing the coatings. In some embodiments, the coatings can be used for medical devices.
Listed below are definitions of various terms used to describe the compositions and methods provided herein. These definitions apply to the terms as they are used throughout this specification and claims, unless otherwise limited in specific instances, either individually or as part of a larger group.
Unless defined otherwise, all technical and scientific terms used herein generally have the same meaning as commonly understood by one of ordinary skill in the art to which the compositions and methods provided herein pertain. Generally, the nomenclature used herein and the laboratory procedures in cell culture, molecular genetics, organic chemistry, and peptide chemistry are those well-known and commonly employed in the art.
As used herein, the articles “a” and “an” refer to one or to more than one (i.e. to at least one) of the grammatical object of the article. By way of example, “an element” means one element or more than one element. Furthermore, use of the term “including” as well as other forms, such as “include”, “includes,” and “included,” is not limiting.
As used herein, the term “about” will be understood by persons of ordinary skill in the art and will vary to some extent on the context in which it is used. As used herein when referring to a measurable value such as an amount, a temporal duration, and the like, the term “about” is meant to encompass variations of ±20% or ±10%, more preferably ±5%, even more preferably ±1%, and still more preferably ±0.1% from the specified value, as such variations are appropriate to perform the disclosed compositions and methods.
Coatings
Surface coatings are described. Thus, in one aspect described are coatings, comprising a base coat and a top coat covalently linked to the base coat, wherein the base coat includes an alkylsilanyl moiety, and the top coat includes a hydrophilic or amphiphilic polymeric moiety having an amine moiety.
In some embodiments, the coating is covalently linked to a surface. Thus, provided herein are surfaces, comprising the coatings described herein covalently linked to the surfaces. In some embodiments, the surface is a surface of a medical device. In some embodiments, the medical device is a catheter, a guide wire, a stent, or an access device. Thus, in some embodiments described are medical devices having a portion of its surface, or all of its surfaces, coated with the one or more of the coatings provided herein. In some embodiments, a medical device is described, comprising a coating described herein covalently linked to a surface of the medical device.
In some embodiments, the polymeric moiety is a p(MEA-co-APMA) polymer, an amine functionalized poly(ethylene glycol) polymer, an amine functionalized poly(vinyl alcohol), an amine functionalized hyaluronic acid, an amine functionalized poly(vinyl pyrrolidone), or a combination thereof.
In some embodiments, the alkylsilanyl moiety is (C1-20 alkyl)silanyl.
In some embodiments, the alkylsilanyl moiety is propylsilanyl, propylmethoxysilanyl, propyldimethoxysilanyl, heptylsilanyl, heptylmethoxysilanyl, heptyldimethoxysilanyl, undecylsilanyl, undecylmethoxysilanyl, undecyldimethoxysilanyl, or a combination thereof.
In some embodiments, the base coat and top coat are covalently linked such that an aminoalkylsilanyl moiety is present.
In some embodiments, the amine moiety is a secondary amine or a tertiary amine.
In some embodiments, the coating is about 100 nanometers thick or less. In some embodiments, the coating is about 10 nanometers thick or less. In some embodiments, the coating is about 1 nanometer thick.
In some embodiments, the coatings include a structure according to Formula I:
In some embodiments, the coatings include a structure according to Formula II:
In some embodiments, the coatings include a structure according to Formula III:
In some embodiments, the coatings include a structure according to Formula IV:
In some embodiments, J is a secondary amine. In some embodiments, J is a tertiary amine. In some embodiments, the coatings provided herein include more than one structure of the Formulae provided such that the coatings include J being a secondary amine on one of the Formulae, and J being a tertiary amine on another of the Formulae.
In some embodiments, the coating includes a combination of the structures selected from Formula II, Formula III, or Formula IV.
A substrate's material composition can be, for example, any metallic/alloy (including, but not limited to, nitinol, stainless steel, cobalt chromium), any plastic/polymer (including, but not limited to, grilamide, Pbax, PEEK), any glass surfaces, any surface including hydroxyl moieties on the surface, or any surface that can be treated to provide hydroxyl moieties on the surface.
The substrates can be virtually in any form. In some embodiments, the substrate is an access device. In some embodiments, the substrate is a catheter. In some embodiments, the substrate is a guide wire. In some embodiments, the substrate is formed into an implantable medical device. In some embodiments, the substrate may be in the form of a flat coupon, hypo tube, wire, woven wire, or laser cut object. In some embodiments, the substrate may be formed into a stent such as a braided stent platform.
One advantage of the coatings provided herein is that they can provide a surface (i.e. of a medical device) having a coating with enhanced durability, enhanced lubricity, or enhanced durability and lubricity.
Coating Processes
In one embodiment, surface modification of a substrate surface is described. In one embodiment, the substrate surface is a hydroxylated substrate surface.
One method of surface functionalizing a substrate is through silane chemistry. Haloalkylsilanes represent one possible compound having reactivity suitable for substrate modification.
In some embodiments, a substrate to be coated is treated with a hydroxylating agent to induce the presence of hydroxyl moieties on the surface. Such hydroxylating agents include, but are not limited to, hydrogen peroxide or plasma treatments.
Once a hydroxylated surface is obtained, a halo-silane (in some embodiments a haloalkylsilane) can be used to activate the surface for amine functional polymer bonding.
In some embodiments, the haloalkylsilane has a structure according to Formula V:
In some embodiments, the haloalkylsilane has a structure according to Formula VI:
In some embodiments, the haloalkylsilane has a structure according to Formula VII:
In some embodiments of these Formulae, X is bromo.
In some embodiments of the Formulae provided herein, R1 is C3-11 alkyl.
In some embodiments of the Formulae provided herein, each of R3, R4, and R5 are, independently, methyl or ethyl. In some embodiments, each of R3, R4, and R5 are methyl.
In some embodiments, X is bromo, and R3 is methyl.
In some embodiments, the haloalkylsilane is halopropylsilanyl, halopropylmethoxysilanyl, halopropyldimethoxysilanyl, haloheptylsilanyl, haloheptylmethoxysilanyl, haloheptyldimethoxysilanyl, haloundecylsilanyl, haloundecylmethoxysilanyl, haloundecyldimethoxysilanyl, or a combination thereof.
In some embodiments, halo is iodo, choro, or bromo. In some embodiments, halo is bromo.
In some embodiments, described herein are processes for forming the coatings described herein, including contacting a haloalkylsilanyl moiety with a polymeric moiety having an amine moiety to form the coating.
In some embodiments, the polymeric moiety is a hydrophilic polymeric moiety. In some embodiments, the polymeric moiety is an amphiphilic polymeric moiety.
In some embodiments, the haloalkylsilanyl moiety is halopropylsilanyl, halopropylmethoxysilanyl, halopropyldimethoxysilanyl, haloheptylsilanyl, haloheptylmethoxysilanyl, haloheptyldimethoxysilanyl, haloundecylsilanyl, haloundecylmethoxysilanyl, haloundecyldimethoxysilanyl, or a combination thereof. In some embodiments, the halo is iodo, chloro, or bromo. In some embodiments, the halo is bromo.
In some embodiments, described herein are processes for coating a medical device, including:
In some embodiments of the processes described herein, the halosilanyl compound is 3-bromopropyltrimethoxysilane, 7-bromoheptyltrimethoxysilane, 11-bromoundecyltrimethoxysilane, or a combination thereof.
In some embodiments, the process is performed with the surface of the medical device at least partially submerged in a solution.
In some embodiments, the processes further comprise a curing step subsequent to forming the base coat and prior to forming the top coat.
In some embodiments, the processes further comprise contacting the surface of the medical device with a hydroxylating agent prior to forming the base coat.
One advantage of the processes provided herein is that a single layer of base coat and top coat can be disposed on the surface, thereby providing a single coating layer on the surface that is on the order of one nanometer thick. By contrast, multiple layers are bonded in traditional guidewire and catheter coating technologies that produce micron thick coatings.
The following Examples further illustrate aspects of the compositions and methods provided herein. However, these Examples are in no way a limitation of the teachings or disclosure as set forth herein. These Examples are provided for illustration purposes.
A coating was applied to electropolished nitinol wires as shown in
The coated nitinol wires prepared in Example 1 were tested using an OakRiver durability and lubricity test system. Tests were performed by pulling the coated nitinol wire through Teflon pad grips set at a clamping force of 900 g. Initial data, shown in
The contents of all references (including literature references, issued patents, published patent applications, and co-pending patent applications) cited throughout this application are hereby expressly incorporated herein by reference in their entireties. Unless otherwise defined, all technical and scientific terms used herein are accorded the meaning commonly known to one of ordinary skill in the art.
Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, numerous equivalents to the specific procedures, embodiments, claims, and examples described herein. Such equivalents are intended to be encompassed by the following claims.
It is to be understood that wherever values and ranges are provided herein, all values and ranges encompassed by these values and ranges, or a combination of these values and ranges, are meant to be encompassed within the scope of the aspects and embodiments provided herein. Moreover, all values that fall within these ranges, as well as the upper or lower limits of a range of values, are also contemplated by the present application.
This application is a continuation of U.S. patent application Ser. No. 17/396,471, now U.S. Pat. No. 11,827,862, filed Aug. 6, 2021, which claims priority of U.S. Provisional Patent Application No. 63/062,995, filed Aug. 7, 2020, the entire content of which is incorporated by reference.
Number | Name | Date | Kind |
---|---|---|---|
4378430 | Modrovich | Mar 1983 | A |
4459317 | Lambert | Jul 1984 | A |
4465770 | Modrovich | Aug 1984 | A |
4487808 | Lambert | Dec 1984 | A |
4842597 | Brook | Jun 1989 | A |
5077352 | Elton | Dec 1991 | A |
5164321 | Zdunek et al. | Nov 1992 | A |
5225267 | Ochi et al. | Jul 1993 | A |
5281468 | Klier et al. | Jan 1994 | A |
5545208 | Wolff et al. | Aug 1996 | A |
5662960 | Hostettler et al. | Sep 1997 | A |
5736251 | Pinchuk | Apr 1998 | A |
5753453 | Kwan | May 1998 | A |
5776661 | Casaletto et al. | Jul 1998 | A |
5804299 | Nakata et al. | Sep 1998 | A |
5888656 | Suzuki et al. | Mar 1999 | A |
6030656 | Hostettler et al. | Feb 2000 | A |
6083257 | Taylor et al. | Jul 2000 | A |
6099562 | Ding et al. | Aug 2000 | A |
6673453 | Beavers et al. | Jan 2004 | B2 |
6706408 | Jelle | Mar 2004 | B2 |
6803069 | Patnaik et al. | Oct 2004 | B2 |
7008979 | Schottman et al. | Mar 2006 | B2 |
7264859 | Rouns et al. | Sep 2007 | B2 |
7494687 | Cox | Feb 2009 | B2 |
7544381 | Kangas | Jun 2009 | B2 |
7544673 | DeWitt et al. | Jun 2009 | B2 |
7553546 | Tan | Jun 2009 | B1 |
7770828 | Matsumoto et al. | Aug 2010 | B2 |
8263720 | Salamone et al. | Sep 2012 | B1 |
10543299 | Baldwin et al. | Jan 2020 | B2 |
11188869 | Subramaniam et al. | Nov 2021 | B2 |
11278649 | Baldwin et al. | Mar 2022 | B2 |
11744925 | Cruise et al. | Sep 2023 | B2 |
11783278 | Subramaniam et al. | Oct 2023 | B2 |
11827862 | Rangwala et al. | Nov 2023 | B2 |
20010021745 | Laginess et al. | Sep 2001 | A1 |
20020082679 | Sirhan et al. | Jun 2002 | A1 |
20020094322 | Lawson et al. | Jul 2002 | A1 |
20020120033 | Jia et al. | Aug 2002 | A1 |
20030069647 | Desmond et al. | Apr 2003 | A1 |
20030187493 | Campbell et al. | Oct 2003 | A1 |
20050055044 | Kangas | Mar 2005 | A1 |
20060052757 | Fischer et al. | Mar 2006 | A1 |
20060121217 | Childs et al. | Jun 2006 | A1 |
20060251795 | Kobrin et al. | Nov 2006 | A1 |
20070154703 | Waller et al. | Jul 2007 | A1 |
20090076596 | Adden et al. | Mar 2009 | A1 |
20090112239 | To | Apr 2009 | A1 |
20090297607 | Wang et al. | Dec 2009 | A1 |
20090324666 | Krongauz et al. | Dec 2009 | A1 |
20100105799 | Rudd et al. | Apr 2010 | A1 |
20100113871 | Dias et al. | May 2010 | A1 |
20100198168 | Rooijmans | Aug 2010 | A1 |
20100236684 | Garlough | Sep 2010 | A1 |
20110000788 | Deschamps et al. | Jan 2011 | A1 |
20110117282 | Bernard et al. | May 2011 | A1 |
20110151000 | Schultz et al. | Jun 2011 | A1 |
20110160382 | Pacetti | Jun 2011 | A1 |
20110183867 | Davies et al. | Jul 2011 | A1 |
20130243936 | Garretson et al. | Sep 2013 | A1 |
20130261566 | Lockwood et al. | Oct 2013 | A1 |
20140011928 | Iwasawa et al. | Jan 2014 | A1 |
20180093019 | Baldwin et al. | Apr 2018 | A1 |
20180325649 | Wu et al. | Nov 2018 | A1 |
20190201589 | Farrell et al. | Jul 2019 | A1 |
20200157374 | Nakabayashi | May 2020 | A1 |
20220162470 | Wu et al. | May 2022 | A1 |
20230303743 | Cruise et al. | Sep 2023 | A1 |
20230381380 | Cruise et al. | Nov 2023 | A1 |
Number | Date | Country |
---|---|---|
2008104573 | Sep 2008 | WO |
2013130850 | Sep 2013 | WO |
2017158148 | Sep 2017 | WO |
2020159881 | Aug 2020 | WO |
2021021642 | Feb 2021 | WO |
2022026689 | Feb 2022 | WO |
Entry |
---|
Bruice, Acid-Base Properties of Amino Acids. Organic Chemistry, Fifth Edition (textbook), Pearson Education Inc., p. 1025 (2007). |
Weber, Use of ionic and zwitterionic (Tris/Bis Tris and HEPES) buffers in studies on hemoglobin function. J. Appl. Physiol., 72(4):1611-1615 (1992). |
Tsai et al., Dopamine-assisted immobilzation of poly(ethylene imine) based polymers for control of cell-surface interactions. Acta Biomaterialia 7, pp. 2518-2525 (2011). |
Nagaoka et al., “Low friction hydrophilic surface for medical devices,” Journal of Bioactive and Compatible Polymers, 5:212-226 (1990). |
Vijay et al., “Acrylic acid-methyl methacrylate copolymer for oral prolonged drug release,” J Mater Sci: Mater Med, 2010, 21, 2583-2592. (Year: 2010). |
Zhu et al., “Polysulfone hemadiafiltration membranes with enhanced anti-fouling and hemocompatibility modified by poly(vinyl pyrrolidone) via in situ cross-linked polymerization,” Material Science and Engineering C 74, 2017, 159-166. (Year: 2017). |
International Search Report and Written Opinion, dated May 30, 2013, for International Application No. PCT/US2013/028380 filed on Feb. 28, 2013. |
International Search Report and Written Opinion, dated Apr. 14, 2020, for International Application No. PCT/US2020/015240 filed on Jan. 27, 2020. |
International Search Report and Written Opinion, mailed Oct. 26, 2020, for International Application No. PCT/US2020/043528 filed on Jul. 24, 2020. |
International Search Report and Written Opinion, dated Nov. 2, 2021, for International Application No. PCT/US2021/043677 filed on Jul. 29, 2021. |
Number | Date | Country | |
---|---|---|---|
20240084210 A1 | Mar 2024 | US |
Number | Date | Country | |
---|---|---|---|
63062995 | Aug 2020 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 17396471 | Aug 2021 | US |
Child | 18511809 | US |